Drug insight: Novel small molecules and drugs for immunosuppression

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 11, 2006, Pages 633-644

  Fantini, Massimo C ^a,b   Becker, Christoph ^b   Kiesslich, Ralf ^b   Neurath, Markus F ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AP 23573; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE INHIBITOR; LEFLUNOMIDE; LENALIDOMIDE; METHYLPREDNISOLONE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NC 1153; PNU 156804; PREDNISOLONE; PREDNISONE; QUINAZOLINE DERIVATIVE; RAPAMYCIN; SEMAPIMOD; TACROLIMUS; TEMSIROLIMUS; TERIFLUNOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; ENTERITIS; GASTROENTEROLOGY; GASTROINTESTINAL DISEASE; GROWTH RETARDATION; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINAL BLEEDING; LIVER TRANSPLANTATION; META ANALYSIS; MOLECULAR DYNAMICS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OSTEOPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT;

ANIMALS; GASTROENTEROLOGY; GASTROINTESTINAL DISEASES; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR WEIGHT;

EID: 33750466870     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0611     Document Type: Review

References (89)

1. H2 polarization in mucosal immunity. Nat Med 8: 567-573
2. Hanauer SB and Present DH (2003) The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 3: 81-92
3. Hong JC and Kahan BD (2000) Immunosuppressive agents in organ transplantation: Past, present, and future. Semin Nephrol 20: 108-125
4. Kino T et al. (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 40: 1256-1265
5. Tanaka H et al. (1987) Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 19: 11-16
6. Harding MW et al. (1989) A receptor for the immunosuppressant FK506 is a cis-trans peptidylprolyl isomerase. Nature 341: 758-760
7. Shaw JP et al. (1988) Identification of a putative regulator of early T cell activation genes. Science 241: 202-205
8. Crabtree GR (1989) Contingent genetic regulatory events in T lymphocyte activation. Science 243: 355-361
9. Lichtiger S et al. (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330: 1841-1845
10. Svanoni F et al. (1998) Effectiveness of cyclosporine A (CsA) in the treatment of active refractory ulcerative colitis (UC) [abstract]. Gastroenterology 114: A1096
11. Van Assche G et al. (2003) Randomized, doubleblind comparison of 4 mg/kg versus 2 mg/g intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125: 1025-1031
12. McDonald JW et al. (2005) Cyclosporine for induction of remission in Crohn's disease. The Cochrane Database of Systematic Reviews, Art. No CD000297
13. Hogenauer C et al. (2003) Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 18: 415-423
14. Baumgart DC, et al. (2003) Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 17: 1273-1281
15. Lucey MR et al. (2005) A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status. Am J Transplant 5: 1111-1119
16. Dumont FJ (2004) ISAtx-247 (Isotechnika/Roche). Curr Opin Investig Drugs 5: 542-550
17. Corral LG and Kaplan G (1999) Immunomodulation by thalidomide and thalidomide analogs. Ann Rheum Dis 58 (Suppl 1): I107-I113
18. Corral LG et al. (1996) Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 2: 506-515
19. Corral LG et al. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 163: 380-386
20. Geitz H et al. (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31: 213-221
21. Bauditz J et al. (2002) Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50: 196-200
22. Abraham RT (1998) Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 10: 330-336
23. Calne RY et al. (1989) Rapamycin for immunosuppression in organ allografting. Lancet 2: 227
24. Kahan BD (1992) Cyclosporin A, FK506, rapamycin: The use of a quantitative analytic tool to discriminate immunosuppressive drug interactions. J Am Soc Nephrol 2 (Suppl): S222-S227
25. Sanchez EQ et al. (2005) Sirolimus conversion after liver transplantation: Improvement in measured glomerular filtration rate after 2 years. Transplant Proc 37: 4416-4423
26. Farkas S et al. (2006) Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis [doi:10.1007/s00384-005-0793-7]
27. Lee SK and Surh CD (2005) Role of interleukin-7 in bone and T-cell homeostasis. Immunol Rev 208: 169-180
28. Sandrini S (2005) Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: A review. Clin Transplant 19: 705-710
29. H1 responses in autoimmunity: IL-12-related cytokines and their receptors. Inflamm Bowel Dis 11: 755-764
30. Leonard WJ et al. (1994) Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: Implications for X-linked severe combined immunodeficiency (XSCID). Adv Exp Med Biol 365: 225-232
31. Asao H et al. (2001) Cutting edge: The common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 167: 1-5
32. Leonard WJ and O'Shea JJ (1998) JAKs and STATs: Biological implications. Annu Rev Immunol 16: 293-322
33. Cetkovic-Cvrlje M et al. (2001) Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 98: 1607-1613
34. Sudbeck EA et al. (1999) Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 5: 1569-1582
35. Uckun FM et al. (2002) Janus kinase 3 inhibitor WHIP-131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood 99: 4192-4199
36. Cetkovic-Cvrlje M et al. (2003) Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Clin Immunol 106: 213-225
37. Linwong W et al. (2005) Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner. Br J Pharmacol 145: 818-828
38. Malavija R et al. (2001) In vivo pharmacokinetics and anti-anaphylactic activity of the novel mast cell inhibitor 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131). Am J Ther 8: 35-39
39. Meydan N et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648
40. Kirken RA et al. (1999) Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol 65: 891-899
41. Wang LH et al. (1999) JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol 162: 3897-3904
42. Behbod F et al. (2001) Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol 166: 3724-3732
43. Stepkowski SM et al. (2005) The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol 175: 4236-4246
44. Changelian PS et al. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878
45. Borie DC et al. (2005) Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 79: 791-801
46. Paniagua R et al. (2005) Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 80: 1283-1292
47. Kudlacz E et al. (2004) The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 4: 51-57
48. Mortellaro A et al. (1999) New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-κB and AP-1 activation. J Immunol 162: 7102-7109
49. Stepkowski SM et al. (2001) PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection. Transplant Proc 33: 3272-3273
50. Stepkowski SM et al. (2002) Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 99: 680-689
51. Prajapati DN et al. (2003) Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 37: 125-128
52. 1 production. J Immunol 160: 1581-1588
53. Brown GR et al. (2000) Naphthyl ketones: A new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett 10: 575-579
54. Tak PP and Firestein GS (2001) NF-κB: A key role in inflammatory diseases. J Clin Invest 107: 7-11
55. Lee JC et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746
56. Kyriakis JM and Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869
57. Pearson G et al. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183
58. Raingeaud J et al. (1996) MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 16: 1247-1255
59. Lee JC et al. (1999) p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther 82: 389-397
60. Kaminska B (2005) MAPK signaling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754: 253-262
61. Waetzig GH et al. (2002) p38 mitogen-activated protein kinase is activated and linked to TNF-α signaling in inflammatory bowel disease. J Immunol 168: 5342-5351
62. Hollenbach E et al. (2004) Inhibition of p38 MAP kinase- and RICK/ NF-κB-signaling suppresses inflammatory bowel disease. FASEB J 18: 1550-1552
63. Badger AM et al. (1996) Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279: 1453-1461
64. Bianchi M et al. (1995) An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol Med 1: 254-266
65. Bianchi M et al. (1996) Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med 183: 927-936
66. Hommes D et al. (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122: 7-14
67. Regan J et al. (2003) Structure-activity relationships of the p38α MAP kinase inhibitor
68. Branger J et al. (2002) Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168: 4070-4077
69. Brahn E et al. (2002) Inhibition of collagen-induced arthritis with an inhibitor of p38 MAP kinase [abstract]. Arthritis Rheum 46 (Suppl): S566
70. Haddad JJ (2001) VX-745. Vertex Pharmaceuticals. Curr Opin Investig Drugs 2: 1070-1076
71. Anselmo DM et al. (2002) FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am J Transplant 2: 843-849
72. Poppe D et al. (2006) Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 176: 640-651
73. + T lymphocytes. J Clin Invest 111: 1133-1145
74. H type 2 development through inhibition of GATA-3 expression. J Immunol 165: 4773-4777
75. Gorelik L et al. (2002) Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 195: 1499-1505
76. - T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172: 5149-5153
77. H1-mediated experimental colitis. Gut 55: 671-680
78. Monteleone G et al. (2001) Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J Clin Invest 108: 601-609
79. Peschon JJ et al. (1994) Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 180: 1955-1960
80. + severe combined immunodeficiency. Nat Genet 20: 394-397
81. Becker TC et al. (2002) Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 195: 1541-1548
82. Schluns KS et al. (2002) Cutting edge: Requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 168: 4827-4831
83. Kennedy MK et al. (2000) Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191: 771-780
84. Cooper MA et al. (2002) In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100: 3633-3638
85. + T cell expansion and function. J Exp Med 201: 139-148
86. Ma HL et al. (2003) IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-γ. J Immunol 171: 608-615
87. Ozaki K et al. (2002) A critical role for IL-21 in regulating immunoglobulin production. Science 298: 1630-1634
88. Schorle H et al. (1991) Development and function of T cells in mice rendered interleukin-2-deficient by gene targeting. Nature 352: 621-624
89. Malek TR (2003) The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 74: 961-965